AlphaMark Advisors LLC Purchases 2,000 Shares of CorMedix Inc. (NASDAQ:CRMD)

AlphaMark Advisors LLC increased its position in shares of CorMedix Inc. (NASDAQ:CRMD) by 16.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,000 shares of the company’s stock after buying an additional 2,000 shares during the period. AlphaMark Advisors LLC’s holdings in CorMedix were worth $113,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC raised its position in shares of CorMedix by 54.3% in the 3rd quarter. FMR LLC now owns 4,618 shares of the company’s stock worth $37,000 after acquiring an additional 1,625 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in CorMedix during the fourth quarter worth approximately $81,000. BNP Paribas Financial Markets increased its holdings in CorMedix by 130.3% in the third quarter. BNP Paribas Financial Markets now owns 11,950 shares of the company’s stock worth $97,000 after purchasing an additional 6,761 shares in the last quarter. Palumbo Wealth Management LLC bought a new stake in CorMedix in the third quarter worth approximately $100,000. Finally, Intech Investment Management LLC acquired a new position in CorMedix in the third quarter valued at approximately $119,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

Insider Activity

In other news, EVP Elizabeth Hurlburt sold 140,027 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $11.18, for a total value of $1,565,501.86. Following the completion of the sale, the executive vice president now owns 45,397 shares in the company, valued at $507,538.46. This represents a 75.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

CRMD has been the subject of several recent analyst reports. Needham & Company LLC raised their price objective on shares of CorMedix from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of CorMedix to a “sell” rating in a report on Friday, November 8th. Truist Financial lifted their price target on shares of CorMedix from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. D. Boral Capital reissued a “buy” rating and set a $15.00 price objective on shares of CorMedix in a research report on Wednesday. Finally, Royal Bank of Canada boosted their target price on CorMedix from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.67.

CorMedix Trading Up 1.0 %

CorMedix stock opened at $12.42 on Friday. The firm’s fifty day moving average price is $9.86 and its two-hundred day moving average price is $8.26. The firm has a market capitalization of $753.65 million, a price-to-earnings ratio of -15.33 and a beta of 1.56. CorMedix Inc. has a 1-year low of $2.89 and a 1-year high of $13.85.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.05. The business had revenue of $11.46 million during the quarter, compared to the consensus estimate of $11.00 million. During the same period in the previous year, the business posted ($0.17) EPS. On average, research analysts forecast that CorMedix Inc. will post -0.32 EPS for the current year.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.